Study Design of a Brazilian Observational Study of Edoxaban in Patients with Atrial Fibrillation (EdoBRA)

被引:0
|
作者
Precoma, Dalton Bertolim [1 ]
da Silva, Rafael Paletta [2 ]
Nakamoto, Allyson [2 ]
Omar, Viviane Mariz [2 ]
Lopes, Danilo [2 ]
Saraiva, Jose Francisco Kerr [3 ,4 ]
机构
[1] Hosp Angelina Caron, Curitiba, PR, Brazil
[2] Daiichi Sankyo Brasil Farmaceut, Sao Paulo, SP, Brazil
[3] Pontificia Univ Catolica Campinas, Campinas, SP, Brazil
[4] Inst Pesquisa Clin Campinas IPECC, Rua Oswaldo Oscar Barthelson 1209, BR-13060080 Campinas, SP, Brazil
关键词
Oral Anticoagulants; Edoxaban; Observational Study; Safety; Efficacy; FACTOR XA INHIBITOR; STROKE PREVENTION; WARFARIN; MULTICENTER; DISEASE;
D O I
10.36660/abc.20230392i
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Clinical trials showed the safety of Edoxaban, a non-vitamin K-dependent oral anticoagulant (NOAC), and its efficacy to prevent stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) patients and also to prevent and treat venous thromboembolism. However, additional research is needed to evaluate the safety and effectiveness of Edoxaban in a real-world scenario in the Brazilian population. Objective: In order to understand the risks and benefits of Edoxaban use in routine clinical settings, the EdoBRA study is being conducted to gain insight into the safety and effectiveness of Edoxaban use in non-preselected patients with NVAF in Brazil. Methods: The EdoBRA study is a multicenter, prospective, observational study conducted in 36 sites in Brazil. NVAF patients >= 18 years treated with commercially available Edoxaban who initiated treatment for at least 14 days and no longer than 90 days prior to enrollment, and who are not simultaneously participating in any interventional study are eligible for this study. Seven hundred patients are planned to be enrolled and one-year of follow up, with data collections expected at baseline and 3, 6, and 12 months after the study enrollment. The primary safety objective is ISTH Clinically Relevant Bleeding, and the secondary effectiveness objective focuses on relevant cardiovascular outcomes related to NVAF. Conclusion: EdoBRA observational study will generate relevant additional information about NOAC Edoxaban on various aspects of patient management in routine care, such as its safety and effectiveness profile in patients with NVAF in Brazil.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
    Lin, Shin-Yi
    Kuo, Ching-Hua
    Ho, Li-Ting
    Liu, Yen-Bin
    Huang, Chih-Fen
    Tang, Sung-Chun
    Jeng, Jiann-Shing
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [42] Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment
    Koretsune, Y.
    Yamashita, T.
    Yasaka, M.
    EUROPEAN HEART JOURNAL, 2013, 34 : 95 - 95
  • [43] Efficacy and safety of edoxaban in elderly patients with atrial fibrillation (AF)
    Lamaida, Norman
    Torella, Giorgio
    Cerciello, Antonio
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N26 - N26
  • [44] Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation A Nationwide Cohort Study
    Yu, Hee Tae
    Yang, Pil-Sung
    Kim, Tae-Hoon
    Jang, Eunsun
    Kim, Daehoon
    Uhm, Jae-Sun
    Kim, Jong-Youn
    Pak, Hui-Nam
    Lee, Moon-Hyoung
    Lip, Gregory Y. H.
    Joung, Boyoung
    STROKE, 2018, 49 (10) : 2421 - 2429
  • [45] Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: The STABLED study
    Sakamoto, Yuki
    Nishiyama, Yasuhiro
    Iwasaki, Yu-Ki
    Daida, Hiroyuki
    Toyoda, Kazunori
    Kitagawa, Kazuo
    Okumura, Ken
    Kusano, Kengo
    Hagiwara, Nobuhisa
    Fujimoto, Shigeru
    Miyamoto, Susumu
    Otsuka, Toshiaki
    Iguchi, Yasuyuki
    Kanamaru, Takuya
    Yamamoto, Teppei
    Kaburagi, Jumpei
    Kimura, Tetsuya
    Matsumoto, Takuyuki
    Kimura, Kazumi
    Shimizu, Wataru
    JOURNAL OF CARDIOLOGY, 2019, 74 (5-6) : 539 - 542
  • [46] Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study
    Okumura, Ken
    Lip, Gregory Y. H.
    Akao, Masaharu
    Tanizawa, Kimihiko
    Fukuzawae, Masayuki
    Abe, Kenji
    Akishita, Masahiro
    Yamashita, Takeshi
    AMERICAN HEART JOURNAL, 2017, 194 : 99 - 106
  • [47] Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients
    Choi, Eue-Keun
    Choi, Jong-Il
    Park, Hyoung-Seob
    Hwang, Gyo-Seung
    Joung, Boyoung
    Kim, Jong-Youn
    Kim, Dae-Hyeok
    Shin, Dong Gu
    Park, Hyung Wook
    JOURNAL OF ARRHYTHMIA, 2023, 39 (04) : 546 - 555
  • [48] OUTCOMES OF LEFT ATRIAL APPENDAGE CLOSURE VERSUS APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION - A RETROSPECTIVE OBSERVATIONAL STUDY
    Patel, Ghanshyam
    Reddy, Shilpa
    Sakiri, Ahmet
    Davis, Jose Moonjely
    Singh, Payal
    Hassan, Omar
    Honganur, Nagaraj Sanchitha
    Naseem, Maania
    Bhatt, Nilay
    Iswarawaka, Saketh
    Qadree, Abdul
    Patel, Yash
    Thakkar, Aditya
    Gupta, Soumya
    Patel, Harsh Dhiren
    Maturi, Bhanu
    Shah, Parth
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 263 - 263
  • [49] Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation An Observational Cohort Study
    Bonde, Anders Nissen
    Lip, Gregory Y. H.
    Kamper, Anne-Lise
    Fosbol, Emil L.
    Staerk, Laila
    Carlson, Nicholas
    Torp-Pedersen, Christian
    Gislason, Gunnar
    Olesen, Jonas Bjerring
    STROKE, 2016, 47 (11) : 2707 - 2713
  • [50] Atrial Fibrillation in Patients with Septic Shock: A One-Year Observational Pilot Study
    Steinberg, Irene
    Brogi, Etrusca
    Pratali, Lorenza
    Trunfio, Danila
    Giuliano, Greta
    Bignami, Elena
    Forfori, Francesco
    TURKISH JOURNAL OF ANAESTHESIOLOGY AND REANIMATION, 2019, 47 (03) : 213 - +